Patents for A61P 35 - Antineoplastic agents (221,099)
06/2008
06/19/2008WO2008073294A2 Inhibition of angiogenesis and tumor growth by inhibitors of beta ii or delta protein kinase c
06/19/2008WO2008072953A1 Statin containing compositions for treatment of cancer
06/19/2008WO2008072849A1 Method of preparing docetaxel and intermediates used therein
06/19/2008WO2008072725A1 Composition containing agaricus blazei murill
06/19/2008WO2008072723A1 ANTI-Claudin-3 MONOCLONAL ANTIBODY, AND TREATMENT AND DIAGNOSIS OF CANCER USING THE SAME
06/19/2008WO2008072655A1 Imidazothiazole derivatives
06/19/2008WO2008072634A1 Fused heterocyclic compound
06/19/2008WO2008072584A1 Liposome encapsulating ammine-platinum complex at high concentration, and method for production of the liposome
06/19/2008WO2008072072A1 Terminally unsaturated vanilloids and medicinal application thereof
06/19/2008WO2008071984A1 Administration of the gonadotropin-releasing hormone antagonist teverelix
06/19/2008WO2008071976A1 8-oxoadenine derivatives as immuno-modulators
06/19/2008WO2008071968A1 Cucurbitacin b and uses thereof
06/19/2008WO2008071742A1 Nanoparticle clusters and methods for forming same
06/19/2008WO2008071701A1 Expression of transgenic t cell receptors in lak-t cells
06/19/2008WO2008071421A1 Nitrate esters of carbonic anhydrase inhibitors
06/19/2008WO2008071404A1 Epothilone analogues modified at positions c12-c13 as anticancer drugs
06/19/2008WO2008071398A1 Sulfonamides and their use as a medicament
06/19/2008WO2008071397A1 Aromatic 1,4-di-carboxylamides and their use
06/19/2008WO2008071387A1 Prodrugs of diphenyl ox- indol- 2 -one compounds for the treatment of cancers
06/19/2008WO2008071242A1 Method for inducing tumor apoptosis by increasing nitric oxide levels
06/19/2008WO2008071173A1 Preparations for inhibiting prostaglandin e2 synthesis
06/19/2008WO2008071093A1 Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10
06/19/2008WO2008071075A1 A process for preparation of extract of broussonetia papyritera and the use thereof in manufacture of a medicament
06/19/2008WO2008070908A1 Chemical compounds and processes
06/19/2008WO2008053219A3 Composition for the treatment of gastrointestinal diseases
06/19/2008WO2008051531A3 Discontinuous methods of treating cancer
06/19/2008WO2008049996A3 Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
06/19/2008WO2008046982A3 New imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular cdc7
06/19/2008WO2008043777B1 Use of monoclonal antibodies specific to the o-acetylated form of gd2 ganglioside for the treatment of certain cancers
06/19/2008WO2008043570A8 Interferon type i supporting compounds
06/19/2008WO2008028965A3 Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
06/19/2008WO2008027584A3 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
06/19/2008WO2008024305A3 Bis (thiohydrazide amides) for treating melanoma
06/19/2008WO2008017828A3 Antibodies specific for human cd98 heavy antigen
06/19/2008WO2008009894A3 Use of imino sugars in immunotherapy
06/19/2008WO2008008482A3 Altered br3-binding polypeptides
06/19/2008WO2007147371B1 Pharmaceutical composition for oral administration
06/19/2008WO2007146968A3 Single-chain multivalent binding proteins with effector function
06/19/2008WO2007144889A3 Treatment of neurofibromatosis
06/19/2008WO2007121447A3 Use of opioid antagonists to attenuate endothelial cell proliferation and migration
06/19/2008US20080146793 Lipid free bacterial capsular polysaccharide for use as antithrombic and antimetastatic agents
06/19/2008US20080146785 Antibody against tumor specific antigen as target
06/19/2008US20080146784 Moncolonal antibody for use in diagnosis and treatment of cell proliferative disorders; immunotherapy; tissue engineering
06/19/2008US20080146662 Methods and compositions for treatment of cancer pain
06/19/2008US20080146660 Androgen receptor antagonists; certain cancers such as colon, skin and prostate cancer, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired
06/19/2008US20080146659 Administering Taxiresinol, (7'R)-7'-Hydroxylariciresinol, Secoisolariciresinol and Isotaxiresinol, which are lignans contained in Hongdoushan contained in Hongdoushan, as the active ingredients for reducing the blood glucose level
06/19/2008US20080146658 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)-4H-chromen-4-one; for modulating functions of estrogen receptor alpha 36, preventing or treating diseases related to estrogen receptor alpha 36, such as asthma, for inducing cell death or inhibiting cell proliferation
06/19/2008US20080146653 Synergistic anti-cancer compositions
06/19/2008US20080146652 Anhydrous formulations formed of diblock copolymer having hydrophilic block and hydrophobic block, an additive selected from a polymer and an organic solvent, the solvent being water-miscible and biocompatible, and a drug; provides for formation of micelles having enhanced ability to incorporate drugs
06/19/2008US20080146648 Less toxicity; side effects redution; administering substituted p-chlorobenzene and a pyrrolethoxybenzene
06/19/2008US20080146639 Reducing the incidence of fibrosis by the co-administration of effective amounts of telmisartan and ramipril; strokes; cardiovascular disorders; organoprotective, tissue-protective, and vasculoprotective effects of combined treatment
06/19/2008US20080146638 primary small cell lung cancer with veliparib and temozolomide; poly/adp-ribose/polymerase (PARP)
06/19/2008US20080146623 Inhibitors of histone deacetylase and prodrugs thereof
06/19/2008US20080146618 CA IX-Specific Inhibitors
06/19/2008US20080146604 adenosine receptor antagonists such as 2-(4-Methoxyphenyl)-9-benzylamino-10-cyano-s-triazolo[1,5-a]quinolin, used for treating respiratory system disorders, vision disorders, tumors, allergies or inflammatory disease, ischemia, hypoxia, arrhythmia or urogential disorders
06/19/2008US20080146599 receptor tyrosine kinase inhibitors such as 2-chloro-N-{3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl}benzenesulfonamide, used as angiogenesis inhibitors in mammals
06/19/2008US20080146598 Combinatorial drug therapy using polymer-drug conjugates
06/19/2008US20080146597 Therapeutic Tetrahydroisoquinoline-Based Compositions for Cancer Therapy
06/19/2008US20080146593 Substituted 5-Phenyl Pyrimidines I In Therapy
06/19/2008US20080146589 Chromenone derivatives
06/19/2008US20080146586 antitumor and antibiotic activity which can be used as anticancer agents; exhibit specific and intensive activity in inhibiting tyrosine kinase of the growth factor receptor, and show negligible side-effects compared
06/19/2008US20080146584 Method of treating cancers using beta-lapachone or analogs or derivatives thereof
06/19/2008US20080146580 Anititumoral Ecteinascidin Derivatives
06/19/2008US20080146578 Indolylmaleimide derivatives
06/19/2008US20080146576 N-(1-Phthalazin-1-ylpiperidin-4-yl)amides as EP2 receptor modulators
06/19/2008US20080146575 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis
06/19/2008US20080146571 potent deoxycytidine kinase inhibitors; O-linked pyrimidin-4-amine-based compounds
06/19/2008US20080146570 Chemical Compounds
06/19/2008US20080146560 1-[4-(4-amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)phenyl]-3-(5-tert-butylisoxazol-3-yl)urea; treatment of tyrosine kinase-induced diseases and conditions, such as angiogenesis, cancer, tumour formation, growth and propagation, arteriosclerosis, ocular diseases, such as age-induced macular degeneration
06/19/2008US20080146556 Poly (ADP-ribose) polymerase 1 inhibitors as radio-sensitization agents of tumors; 7-methoxy-1,2,3,11-tetrahydro-5,11-diaza-benzo[a]trindene-4,6-dione
06/19/2008US20080146555 Uses of Kinase Inhibitors and Compositions Thereof
06/19/2008US20080146547 e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases
06/19/2008US20080146545 Macrocyclic compounds useful as inhibitors of kinases and HSP90
06/19/2008US20080146542 Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof
06/19/2008US20080146531 Therapeutically Active Triazoles and Their Use
06/19/2008US20080146528 stilbene phosphate derivatives; anticarcinogenic agents; bactericide, fungicide; veterinary medicine
06/19/2008US20080146522 Inflammation, allergic diseases, metastatic cancers, pathogen infections; glycosaminoglycan related molecules
06/19/2008US20080146510 For suppressing cell proliferation/tumor growth or modulating immune system by transformation of T-lymphocytes or enhancement of natural killer cells
06/19/2008US20080146507 Methods and Compositions for Using MHC Class II Invariant Chain Polypeptide as a Receptor for Macrophage Migration Inhibitory Factor
06/19/2008US20080146505 47 Human Secreted Proteins
06/19/2008US20080146503 albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins
06/19/2008US20080146488 strongly immunogenic polypeptide to a more weakly immunogenic polypeptide can precipitate and focus a CpG adjuvant to increase in vivo priming of a cytotoxic T-lymphocyte (CTL) response, and thus increase the immunogenicity of the more weakly immunogenic polypeptide
06/19/2008US20080145884 Sfrp and peptide motifs that interact with sfrp and methods of their use
06/19/2008US20080145866 Modified human thymic stromal lymphopoietin
06/19/2008US20080145859 Diagnosis and treatment of cancer
06/19/2008US20080145464 Anti-tumor and anti-inflammatory extracts of plant biomass and their uses
06/19/2008US20080145453 4-(piperimidine-2thione)phenyl derivatives; kinesin Eg5 inhibitor; anticarcinogenic agent; the aldehyde, the ketone and the thiourea are reacted together in the solid phase, grafted onto resin by esterification, and detached by hydrolysis
06/19/2008US20080145450 Delivery or removal of metals from biological systems
06/19/2008US20080145441 Core of metal atoms of gold, silver or copper covalently linked to a carbohydrate group and to at least 20 ligands
06/19/2008US20080145440 Cisplatin intercalated into the double-helical DNA; stably retains cisplatin and exhibits an excellent slow-release property
06/19/2008US20080145416 Cross-linked ionic core micelles
06/19/2008US20080145414 Method of Producing Fine Particles Surface-Modified with Water-Soluble Substance
06/19/2008US20080145413 Lipids and lipid assemblies comprising transfection enhancer elements
06/19/2008US20080145387 N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(-9-tetradeceneyloxy)-1 -propanaminium salt; cytofectin and lipid mixture
06/19/2008US20080145382 (CTLA-4, Cytotoxic T-Lymphocyte Antigen-4); vaccines, feline immunomodulators, antitumor agents; treating feline viral diseases; veterinary medicine
06/19/2008US20080145380 Algae and cancer treatment
06/19/2008US20080145377 G-CSF Polypeptides And Uses Thereof
06/19/2008US20080145375 Vaccination
06/19/2008US20080145372 Bioreductively-Activated Prodrugs
06/19/2008US20080145368 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias